Alternative Splicing in the α-Galactosidase A Gene: Increased Exon Inclusion Results in the Fabry Cardiac Phenotype  Satoshi Ishii, Shoichiro Nakao, Reiko.

Slides:



Advertisements
Similar presentations
Figure 1. RT–PCR identification of an abnormal transcript of the PTPN6 gene in normal and leukemic bone marrow cells and cell line. (a) Diagrammatic representation.
Advertisements

Volume 27, Issue 6, Pages (September 2007)
Characterization of the Human Platelet/Endothelial Cell Adhesion Molecule-1 Promoter: Identification of a GATA-2 Binding Element Required for Optimal Transcriptional.
Crucial Roles of MZF1 and Sp1 in the Transcriptional Regulation of the Peptidylarginine Deiminase Type I Gene (PADI1) in Human Keratinocytes  Sijun Dong,
A novel donor splice site characterized by CFTR mRNA analysis induces a new pseudo- exon in CF patients  Lucy Costantino, Laura Claut, Valentina Paracchini,
Volume 11, Issue 6, Pages (June 2003)
Molecular characterization of in-frame and out-of-frame alternative splicings in coagulation factor XI pre-mRNA by Rosanna Asselta, Valeria Rimoldi, Ilaria.
Volume 64, Issue 6, Pages (June 2016)
Mutation Spectrum of the Survival of Motor Neuron 1 and Functional Analysis of Variants in Chinese Spinal Muscular Atrophy  Yu-jin Qu, Jin-li Bai, Yan-yan.
Regulation of expression of murine transferrin receptor 2
Betaine, Dimethyl Sulfoxide, and 7-Deaza-dGTP, a Powerful Mixture for Amplification of GC-Rich DNA Sequences  Marco Musso, Renata Bocciardi, Sara Parodi,
Splicing defects in the CFTR gene: Minigene analysis of two mutations, G>C and A>G  Gwendal Dujardin, Diane Commandeur, Catherine Le Jossic-Corcos,
Truncation of Glycoprotein (GP) IIIa (▵ ) Prevents Complex Formation With GPIIb: Novel Mutation in Exon 11 of GPIIIa Associated With Thrombasthenia.
The homeodomain protein Cdx2 regulates lactase gene promoter activity during enterocyte differentiation  Rixun Fang, Nilda A. Santiago, Lynne C. Olds,
Volume 10, Issue 1, Pages (July 2002)
by Guang Yang, Shu-Ching Huang, Jane Y. Wu, and Edward J. Benz
A Three Amino Acid Deletion in Glycoprotein IIIa Is Responsible for Type I Glanzmann's Thrombasthenia: Importance of Residues Ile325Pro326Gly327 for β3.
Eija Siintola, Meral Topcu, Nina Aula, Hannes Lohi, Berge A
Mutations in the Liver Glycogen Phosphorylase Gene (PYGL) Underlying Glycogenosis Type VI (Hers Disease)  Barbara Burwinkel, Henk D. Bakker, Eliezer Herschkovitz,
Marco Baralle, Tibor Pastor, Erica Bussani, Franco Pagani 
by Kwang-Hyun Baek, Michelle A
GRACILE Syndrome, a Lethal Metabolic Disorder with Iron Overload, Is Caused by a Point Mutation in BCS1L  Ilona Visapää, Vineta Fellman, Jouni Vesa, Ayan.
Cloning of Dimethylglycine Dehydrogenase and a New Human Inborn Error of Metabolism, Dimethylglycine Dehydrogenase Deficiency  Barbara A. Binzak, Ron.
IFN-γ Upregulates Expression of the Mouse Complement C1rA Gene in Keratinocytes via IFN-Regulatory Factor-1  Sung June Byun, Ik-Soo Jeon, Hyangkyu Lee,
Reccurrent F8 Intronic Deletion Found in Mild Hemophilia A Causes Alu Exonization  Yohann Jourdy, Alexandre Janin, Mathilde Fretigny, Anne Lienhart, Claude.
Structural and Functional Mutations of the Perlecan Gene Cause Schwartz-Jampel Syndrome, with Myotonic Myopathy and Chondrodysplasia  Eri Arikawa-Hirasawa,
Rose-Anne Romano, Barbara Birkaya, Satrajit Sinha 
Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice  Yimin Hua, Timothy A. Vickers, Hazeem L. Okunola,
Screening for genes up-regulated in 5/6 nephrectomized mouse kidney
Novel Mutations in the LAMC2 Gene in Non-Herlitz Junctional Epidermolysis Bullosa: Effects on Laminin-5 Assembly, Secretion, and Deposition  Daniele Castiglia,
Exon Circularization Requires Canonical Splice Signals
Volume 25, Issue 9, Pages (September 2017)
Double Heterozygosity for a RET Substitution Interfering with Splicing and an EDNRB Missense Mutation in Hirschsprung Disease  Alberto Auricchio, Paola.
Analysis of Rare APC Variants at the mRNA Level
Structure of the GM2A Gene: Identification of an Exon 2 Nonsense Mutation and a Naturally Occurring Transcript with an In-Frame Deletion of Exon 2  Biao.
Volume 18, Issue 2, Pages (April 2005)
Volume 27, Issue 6, Pages (September 2007)
Volume 20, Issue 3, Pages (March 1998)
Identification and Sequencing of a Putative Variant of Proopiomelanocortin in Human Epidermis and Epidermal Cells in Culture  Gong Can, Zalfa Abdel-Malek,
Propionic and Methylmalonic Acidemia: Antisense Therapeutics for Intronic Variations Causing Aberrantly Spliced Messenger RNA  A. Rincón, C. Aguado, L.R.
Jung-Ok Han, Sharri B Steen, David B Roth  Molecular Cell 
Pseudoexon Activation as a Novel Mechanism for Disease Resulting in Atypical Growth- Hormone Insensitivity  Louise A. Metherell, Scott A. Akker, Patricia.
A Homozygous Nonsense Mutation in Type XVII Collagen Gene (COL17A1) Uncovers an Alternatively Spliced mRNA Accounting for an Unusually Mild Form of Non-Herlitz.
A Presenilin-1 Truncating Mutation Is Present in Two Cases with Autopsy-Confirmed Early-Onset Alzheimer Disease  Carolyn Tysoe, Joanne Whittaker, John.
Transcriptional Regulation of ATP2C1 Gene by Sp1 and YY1 and Reduced Function of its Promoter in Hailey–Hailey Disease Keratinocytes  Hiroshi Kawada,
Fabry Disease: Novel α-Galactosidase A 3′-Terminal Mutations Result in Multiple Transcripts Due to Aberrant 3′-End Formation  Makiko Yasuda, Junaid Shabbeer,
RAD51 is essential for L. donovani.
Keratinocyte growth factor promotes goblet cell differentiation through regulation of goblet cell silencer inhibitor  Dai Iwakiri, Daniel K. Podolsky 
Volume 3, Issue 1, Pages (January 2001)
Reccurrent F8 Intronic Deletion Found in Mild Hemophilia A Causes Alu Exonization  Yohann Jourdy, Alexandre Janin, Mathilde Fretigny, Anne Lienhart, Claude.
Volume 54, Issue 1, Pages (July 1998)
Analysis of GNAS1 and Overlapping Transcripts Identifies the Parental Origin of Mutations in Patients with Sporadic Albright Hereditary Osteodystrophy.
Assessing the Functional Characteristics of Synonymous and Nonsynonymous Mutation Candidates by Use of Large DNA Constructs  A.M. Eeds, D. Mortlock, R.
The Pro162 Variant is a Loss-of-Function Mutation of the Human Melanocortin 1 Receptor Gene  Celia Jiménez-Cervantes, Concepción Olivares, Petra González,
Wook Lew  Journal of Investigative Dermatology 
Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers  Ryoichi Onozato, MD,
Anthony M. Raizis, Martin M. Ferguson, David T. Nicholls, Derek W
Identification of Skn-1n, a Splice Variant Induced by High Calcium Concentration and Specifically Expressed in Normal Human Keratinocytes  Koji Nakajima,
A Second Leaky Splice-Site Mutation in the Spastin Gene
Bart A. Jessen, Marjorie A. Phillips, Robert H. Rice 
Jiamiao Lu, Feijie Zhang, Mark A Kay  Molecular Therapy 
Identification and Characterization of a Mutation, in the Human UDP-Galactose-4- Epimerase Gene, Associated with Generalized Epimerase-Deficiency Galactosemia 
Cloning of Dimethylglycine Dehydrogenase and a New Human Inborn Error of Metabolism, Dimethylglycine Dehydrogenase Deficiency  Barbara A. Binzak, Ron.
Mutation of the Ca2+ Channel β Subunit Gene Cchb4 Is Associated with Ataxia and Seizures in the Lethargic (lh) Mouse  Daniel L Burgess, Julie M Jones,
Richard J. Wenstrup, Jane B. Florer, Marcia C
RhoH is underexpressed in HCL mediated by a transcriptional mechanism.
Familial Porphyria Cutanea Tarda: Characterization of Seven Novel Uroporphyrinogen Decarboxylase Mutations and Frequency of Common Hemochromatosis Alleles 
Exon Skipping in IVD RNA Processing in Isovaleric Acidemia Caused by Point Mutations in the Coding Region of the IVD Gene  Jerry Vockley, Peter K. Rogan,
A Splicing-Independent Function of SF2/ASF in MicroRNA Processing
Identification of Novel pro-α2(IX) Collagen Gene Mutations in Two Families with Distinctive Oligo-Epiphyseal Forms of Multiple Epiphyseal Dysplasia  Paul.
Presentation transcript:

Alternative Splicing in the α-Galactosidase A Gene: Increased Exon Inclusion Results in the Fabry Cardiac Phenotype  Satoshi Ishii, Shoichiro Nakao, Reiko Minamikawa-Tachino, Robert J. Desnick, Jian-Qiang Fan  The American Journal of Human Genetics  Volume 70, Issue 4, Pages 994-1002 (April 2002) DOI: 10.1086/339431 Copyright © 2002 The American Society of Human Genetics Terms and Conditions

Figure 1 Identification of the mutant α-Gal A cDNA. A, To determine the sequence of the cDNA at the junction between exons 4 and 5, RT-PCR amplification of 0.1 μg of total RNA, prepared from the patient's lymphoblasts and from normal lymphoblasts, was performed using primers 5′-GTCCTTGGCCCTGAATAG-3′ and 5′-GTCCAGCAACATCAACAATT-3′, and the results were analyzed by agarose gel electrophoresis. Lane 1, patient lymphoblasts; lane 2, normal lymphoblasts. B, To analyze the sequence of mutant α-Gal A cDNA, the RT-PCR product amplified with the above primers was subcloned into the TA cloning pCR vector (Invitrogen), and the mutant cDNA fragment was sequenced by an automated sequencer. The American Journal of Human Genetics 2002 70, 994-1002DOI: (10.1086/339431) Copyright © 2002 The American Society of Human Genetics Terms and Conditions

Figure 2 Transient expression of mutant α-Gal A cDNA in COS-1 cells. COS-1 cells were transfected with 1 μg of plasmid DNA and 8 μl of LipofectAMINE Reagent (Life Technologies). A, Western blot analysis was performed using a rabbit anti-human α-Gal A antibody, as described elsewhere (Ishii et al. 1994). Lane 1, mock transfection (pBactE vector; see Koide et al. 1990); lane 2, pBaIns57, an α-Gal A cDNA containing the 57-nt intronic insertion; lane 3, pBaN, a wild-type α-Gal A expression construct (Ishii et al. 1992). Approximately 50 μg of protein was loaded in each well for SDS-PAGE analysis. The truncated protein is indicated by an arrow. B, α-Gal A activity was assayed with 4-methylumbelliferyl α-D-galactoside, as described by Fan et al. (1999). Bars 1, 2, and 3 in the graph correspond to lanes 1, 2, and 3, respectively, in panel A. The enzyme activity is expressed as the mean±SD of triplicate experiments. The American Journal of Human Genetics 2002 70, 994-1002DOI: (10.1086/339431) Copyright © 2002 The American Society of Human Genetics Terms and Conditions

Figure 3 Quantitative analysis of the mutant α-Gal A mRNA. The relative amounts of normal and mutant α-Gal A mRNA were determined by a competitive RT-PCR method (Becker-Andre and Hahlbrock 1989). The concentration of total RNA prepared from the lymphoblasts was determined by OD260 and was adjusted using the human β-actin Competitive PCR Set (Takara Shuzo). RT was performed with 0.6 μg of total RNA in 60 μl of the reaction mixture, through use of the RNA PCR Kit (Takara Shuzo). Aliquots (5 μl) of the RT reaction were used for PCR amplifications of mutant or total α-Gal A mRNAs. A, Diagram of mutant α-Gal A mRNA and the location of the primers. In the assay of mutant α-Gal A mRNA, target (298 bp) and competitor (249 bp) DNA fragments were amplified with primer set P1 (5′-GCTCCACACTATTTGGAAG-3′) and P2 (5′-AAAGGAGCAGCCATGATAG-3′) and DNA competitors prepared specifically for the mutant α-Gal A mRNA (see text) at various concentrations. In the assay for the total α-Gal A mRNA, target (324 bp) and competitor (275 bp) DNA fragments were amplified with primers P3 (5′-GGTTGGAATGACCCAGATA-3′) and P4 (5′-TGCGATGGTATAAGAGCG-3′) and DNA competitors prepared specifically for the total α-Gal A mRNA (both mutant and normal) at various concentrations. The relative amounts of the total α-Gal A mRNA (B) and the mutant α-Gal A mRNA (C) in both the patient's lymphoblasts and the normal lymphoblasts were determined by comparison with the competitors' concentration, indicated at the top of the photos. D, After agarose gel electrophoresis, the concentrations of the PCR products were determined using an image processing system, according the method reported elsewhere (Minamikawa-Tachino et al. 1993). Circles = patient; triangles = unaffected subject; Ex = exon; T = target; C = competitor. The American Journal of Human Genetics 2002 70, 994-1002DOI: (10.1086/339431) Copyright © 2002 The American Society of Human Genetics Terms and Conditions

Figure 4 Alternative splicing in human tissues. RT-PCR was performed with 0.1 μg of total human tissue RNA obtained from OriGene, as described in the legend to figure 1. Lane 1, heart; lane 2, kidney; lane 3, spleen; lane 4, liver; lane 5, small intestine; lane 6, muscle; lane 7, lung; lane 8, lymphoblasts. The American Journal of Human Genetics 2002 70, 994-1002DOI: (10.1086/339431) Copyright © 2002 The American Society of Human Genetics Terms and Conditions

Figure 5 Contribution of nucleotide at nt 9331 to alternative splicing. A, Sequence of α-Gal A intron 4 from the patient. The 57-nt sequence is enclosed in the box. The G→A transition at nt 9331 is indicated by an arrow. The polypyrimidine tract is indicated by double underlining. B, Transient expression of minigene constructs in COS-1 cells. Minigene constructs containing the entire normal or mutant intron 4 were prepared as follows: fragment A (nts 8324–9450) was amplified, from genomic DNA of an unaffected subject, with primers 5′-ATAAGCACATGTCCTTGGC-3′ and 5′-TGCAGAGATAATGAGGGAAT-3′ and then was digested with AflIII and SacI; fragment B (nts 9112–10282) was amplified from normal or mutant genomic DNA with primers 5′-CTGCCTAGAACAGTTCTTC-3′ and 5′-TCATTCCAACCCCCTGGT-3′, followed by digestion with SacI and BstXI. The 951-bp AflIII-SacI–digested fragment A was ligated to the 992-bp SacI-BstXI–digested fragment B, to generate a 1,943-bp AflIII-BstXI fragment that was inserted into the AflIII-BstXI of the pCXN2Gal expression construct (Ishii et al. 1993). The constructs containing normal and patient intron 4 were designated as “pCXN2Gal/Int4N” and “pCXN2Gal/Int4P,” respectively. To generate the G→C and G→T conversions at the nt 9331 mutation site, site-directed mutagenesis by Pfu-polymerase–based PCR using the QuickChange kit (Stratagene) was performed in a small fragment (SacI-XmaI, nts 9282–9587) of α-Gal A intron 4. The complete sequence of the mutated fragment was confirmed by DNA sequencing. The fragment with the desired mutation was subcloned into its original position in a minigene construct using two steps of subcloning. First it was inserted into a vector containing NheI-XmaI (exons 2–4 [nts 358–639 of cDNA] and intron 4 [nts 8413–9587 of genomic DNA]). Next, it was transferred to the pCXN2 expression vector that contains the full-length α-Gal A cDNA and intron 4. The constructs containing the G→C or G→T conversion are designated “pCXN2Gal/Int4C” or “pCXN2Gal/Int4T,” respectively. COS-1 cells transfected with 1 μg of plasmid DNA were grown for 2 d, and RT-PCR analysis was performed using primer pair 5′-GTCCTTGGCCCTGAATAG-3′ and 5′-GTCCAGCAACATCAACAATT-3′ and total RNA prepared from COS-1 cells transfected with each plasmid construct. Lane 1, mock transfection, pCXN2 vector (Niwa et al. 1991); lane 2, pCXN2Gal/Int4N; lane 3, pCXN2Gal/Int4P; lane 4, pCXN2Gal/Int4T; lane 5, pCXN2Gal/Int4C. The American Journal of Human Genetics 2002 70, 994-1002DOI: (10.1086/339431) Copyright © 2002 The American Society of Human Genetics Terms and Conditions

Figure 6 Detection of the mutation in unrelated patients with cardiac Fabry disease. The mutation can be readily detected by restriction enzyme analysis, because the G→A transition at nt 9331 disrupts a BfaI cleavage site. The mutant 334-bp fragment was not digested, whereas the normal fragment was cleaved into fragments of 212 bp and 122 bp. A, PCR fragment (334 bp; nts 9117–9450) amplified from genomic DNA with primers 5′-TAGAACAGTTCTTCCCCAA-3′ and 5′-TGCAGAGATAATGAGGGAAT-3′, digested with BfaI (New England Biolabs) and analyzed by agarose gel electrophoresis. B, RT-PCR analyses performed as described in the legend to figure 1, through use of total RNA from normal lymphoblasts or patient lymphoblasts. Lane 1, unaffected; lanes 2 and 3, probands 1 and 2; lanes 4, 5, 6, and 7, patients 2, 3, 6, and 7, respectively, all with Fabry disease and reported previously as having decreased α-Gal A mRNA content (Nakao et al. 1995); lane 8, patient with Fabry disease who has the M296I mutation (Nakao et al. 1995); lane 9, patient with Fabry disease who has the R301Q mutation (Sakuraba et al. 1990). The American Journal of Human Genetics 2002 70, 994-1002DOI: (10.1086/339431) Copyright © 2002 The American Society of Human Genetics Terms and Conditions